Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This international, multicenter, prospective single arm Phase II biomarker discovery clinical
trial with the primary objective of assessing the association of PFS with gene mutations,
gene copy number aberrations and gene signatures in post-menopausal women with hormone
receptor positive, HER2-negative metastatic or locally relapsed breast cancer whose disease
has progressed after prior adjuvant endocrine therapy or one line systemic treatment, i.e.,
endocrine treatment or chemotherapy, administered for metastatic disease.